IPM Take
For decades, women with irregular periods, infertility, acne or excess hair growth were directed towards gynaecology.
Their cardiovascular risk often remained in another building.
A study involving more than two million women now links PMOS with sharply higher rates of heart attack, stroke, transient ischaemic attack and peripheral artery disease, even after recognised cardiovascular risk factors were considered.
The evidence is observational and does not prove that PMOS directly causes these events. Absolute cardiovascular risk also remains relatively low in younger women.
But health systems no longer have a credible excuse for treating PMOS as a reproductive problem that becomes irrelevant once pregnancy is no longer the priority.
The name has changed. The care pathway must follow.
Executive Summary
Researchers analysed US insurance claims involving more than two million women aged 18 to 50, including more than 400,000 with polyendocrine metabolic ovarian syndrome, formerly known as polycystic ovary syndrome. The retrospective longitudinal study is the largest US analysis examining the relationship between PMOS and atherosclerotic cardiovascular disease.
After adjustment for recorded risk factors, including obesity, diabetes, hypertension and dyslipidaemia, women with PMOS were approximately 2.5 times more likely to experience a heart attack or stroke during the study period. They were 3.4 times more likely to experience a transient ischaemic attack and almost four times more likely to have peripheral artery disease.
These are relative estimates from administrative claims data. The study cannot prove that PMOS caused the cardiovascular events, and unmeasured factors may have influenced the findings. Independent experts also stressed that absolute cardiovascular event rates remain low among younger women.
International guidance already recommends cardiovascular risk-factor assessment for all women with PMOS, including a lipid profile at diagnosis, annual blood-pressure measurement and periodic glycaemic assessment.
Why it matters
- Policymakers and public authorities: Cardiovascular prevention programmes should recognise PMOS as a female-specific risk marker rather than leaving it confined to reproductive health policy.
- Primary care clinicians: A PMOS diagnosis should trigger structured assessment of blood pressure, cholesterol, glucose, smoking and other cardiovascular risks.
- Cardiologists, endocrinologists and gynaecologists: Care should not end at the boundaries between specialties. Clear referral and long-term follow-up pathways are needed.
- Patients and advocates: Women should be informed about cardiovascular risk without being frightened, blamed for their weight or told that lifestyle change is their only option.
- Researchers: Prospective studies are needed to establish absolute risk, clarify biological mechanisms and determine whether treatments reduce cardiovascular events.
For years, the typical PMOS story began with a missed period.
It moved through acne, unwanted hair growth, weight changes or difficulty becoming pregnant. The patient was sent to gynaecology. Treatment focused on menstrual regulation, fertility or visible symptoms.
The heart was rarely part of the conversation.
A major US study suggests that must change.
Researchers examined health insurance data from more than two million women aged 18 to 50, including over 400,000 diagnosed with PMOS, the condition until recently known as polycystic ovary syndrome. Women with PMOS experienced more atherosclerotic cardiovascular disease, including heart attacks and strokes.
The difference remained after researchers adjusted for obesity, diabetes, hypertension and abnormal cholesterol.
Women with PMOS were approximately 2.5 times more likely to have a heart attack or stroke during the study period. Their likelihood of experiencing a transient ischaemic attack was 3.4 times higher, while peripheral artery disease was almost four times more common.
Those figures are striking.
They are also easy to sensationalise.
A 2.5-fold relative increase does not mean most young women with PMOS will experience a heart attack. Cardiovascular events remain uncommon before menopause, and the research does not justify routine cardiac imaging or specialist referral for every patient.
What it does justify is structured prevention.
Large numbers, real limitations
The study’s scale is its greatest strength. It allowed researchers to examine serious cardiovascular events that are relatively rare among younger women.
But the analysis relied on insurance claims originally collected for healthcare administration and billing. Diagnoses may have been missed or coded incorrectly. Information on smoking, physical activity, family history, diet and disease severity may also have been incomplete.
Women with PMOS may interact with healthcare services more frequently, increasing the chance that other conditions are detected.
The study therefore demonstrates a strong association. It cannot prove that PMOS directly caused the events.
The appropriate message is not panic.
It is that youth should no longer be used as a reason to ignore cardiovascular risk.
The new name exposes an old care failure
In May 2026, an international consensus renamed polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome.
The change was intended to correct a misleading focus on ovarian “cysts” and acknowledge the condition’s wider hormonal, metabolic, psychological and reproductive effects. More than 50 patient and professional organisations participated in the renaming process.
The new cardiovascular findings give that change immediate clinical relevance.
If PMOS is understood as a lifelong endocrine and metabolic condition, it cannot remain trapped inside fertility services.
A woman should not need to be planning a pregnancy before her cholesterol, blood pressure or glucose becomes clinically important.
The guidance exists. Delivery is the problem
International guidance already recommends assessing cardiovascular risk factors in all women with PMOS.
Women should receive a lipid profile at diagnosis regardless of age or BMI. Blood pressure should be measured annually. Glycaemic status should be checked at diagnosis and reassessed every one to three years according to individual risk.
These are not expensive or experimental interventions.
The problem is ownership.
A gynaecologist may diagnose PMOS. An endocrinologist may manage metabolic complications. A fertility specialist may support conception. Primary care may be expected to monitor long-term risk, often without a clearly defined transfer of responsibility.
Every clinician sees one part of the patient.
The patient is left carrying the pathway between them.
A diagnosis made in adolescence or early adulthood may be followed by years without structured metabolic review. Menstrual symptoms may improve while blood pressure, glucose and cholesterol quietly worsen.
Health systems do not necessarily need a specialist PMOS centre for every patient.
They do need to ensure that someone checks.
Prevention cannot become weight blame
Cardiovascular prevention includes supporting physical activity, smoking cessation, healthy nutrition and weight management where appropriate.
But PMOS care has often reduced complex metabolic risk to a single instruction: lose weight.
That is inadequate, particularly because the new study found elevated cardiovascular risk even after obesity and other recognised risk factors were considered.
International guidance also warns healthcare professionals to recognise weight stigma and consider disordered eating when discussing lifestyle interventions.
A clinician should not record a high BMI, advise weight loss and consider the cardiovascular assessment complete.
Blood pressure must be measured, lipids must be tested, glycaemic risk must be assessed.
Where hypertension, diabetes or dyslipidaemia is identified, evidence-based treatment should follow.
A name change will not change care by itself
The study should not trigger alarmist screening programmes.
It should trigger better routine medicine.
Most younger women with PMOS will not experience a heart attack or stroke. Advanced cardiovascular testing is not justified solely by the diagnosis.
But basic risk-factor assessment is affordable, available and already recommended.
The political failure would be turning a major publication and a global name change into another awareness campaign without changing delivery.
A new name will not lower blood pressure.
A press release will not test cholesterol.
Telling women they are at risk without creating access to prevention merely transfers anxiety from the health system to the patient.
PMOS was never only about ovaries.
The cardiovascular evidence is making that increasingly difficult to ignore.
